Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
Int J Mol Sci ; 25(14)2024 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-39063198

RESUMEN

Anti-IgLON5 (IgLON5-IgG)-associated disease is a newly defined clinical entity. This literature review aims to evaluate its pathogenesis, which remains a pivotal question. Features that favour a primary neurodegenerative mechanism include the non-inflammatory tauopathy neuropathological signature and overrepresentation of microtubule-associated protein tau (MAPT) H1/H1 genotype as seen in other sporadic tauopathies. In contrast, the cell-surface localisation of IgLON5, capability of anti-IgLON5 antibodies to exert direct in vitro pathogenicity and disrupt IgLON5 interactions with its binding partners, human leukocyte antigen (HLA)-DRB1*10:01 and HLA-DQB1*05:01 allele preponderance with high affinity binding of IgLON5 peptides, and responsiveness to immunotherapy favour a primary autoimmune process. The presentation and course of anti-IgLON5-associated disease is heterogenous; hence, we hypothesise that a multitude of immune mechanisms are likely simultaneously operational in this disease cohort.


Asunto(s)
Moléculas de Adhesión Celular Neuronal , Inmunoglobulina G , Humanos , Moléculas de Adhesión Celular Neuronal/inmunología , Moléculas de Adhesión Celular Neuronal/genética , Moléculas de Adhesión Celular Neuronal/metabolismo , Inmunoglobulina G/inmunología , Inmunoglobulina G/metabolismo , Tauopatías/inmunología , Tauopatías/genética , Tauopatías/metabolismo , Animales , Proteínas tau/inmunología , Proteínas tau/metabolismo , Proteínas tau/genética , Autoanticuerpos/inmunología
2.
Artículo en Inglés | MEDLINE | ID: mdl-38744459

RESUMEN

BACKGROUND: We sought to identify an optimal oral corticosteroid regimen at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which would delay time to first relapse while minimising cumulative corticosteroid exposure. METHODS: In a retrospective multicentre cohort study, Cox proportional hazards models examined the relationship between corticosteroid course as a time-varying covariate and time to first relapse. Simon-Makuch and Kaplan-Meier plots identified an optimal dosing strategy. RESULTS: We evaluated 109 patients (62 female, 57%; 41 paediatric, 38%; median age at onset 26 years, (IQR 8-38); median follow-up 6.2 years (IQR 2.6-9.6)). 76/109 (70%) experienced a relapse (median time to first relapse 13.7 months; 95% CI 8.2 to 37.9). In a multivariable model, higher doses of oral prednisone delayed time to first relapse with an effect estimate of 3.7% (95% CI 0.8% to 6.6%; p=0.014) reduced hazard of relapse for every 1 mg/day dose increment. There was evidence of reduced hazard of relapse for patients dosed ≥12.5 mg/day (HR 0.21, 95% CI 0.07 to 0.6; p=0.0036), corresponding to a 79% reduction in relapse risk. There was evidence of reduced hazard of relapse for those dosed ≥12.5 mg/day for at least 3 months (HR 0.12, 95% CI 0.03 to 0.44; p=0.0012), corresponding to an 88% reduction in relapse risk compared with those never treated in this range. No patient with this recommended dosing at onset experienced a Common Terminology Criteria for Adverse Events grade >3 adverse effect. CONCLUSIONS: The optimal dose of 12.5 mg of prednisone daily in adults (0.16 mg/kg/day for children) for a minimum of 3 months at the onset of MOGAD delays time to first relapse.

3.
J Neurol Neurosurg Psychiatry ; 95(6): 544-553, 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38290838

RESUMEN

BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients. METHODS: MOG-IgG-seropositive confirmed adult MOGAD patients were included (n=202). Serum MOG-IgG and epitope binding were determined by validated flow cytometry live cell-based assays. Associations between epitopes, disease course, clinical phenotype, Expanded Disability Status Scale and Visual Functional System Score at onset and last review were evaluated. RESULTS: Of 202 MOGAD patients, 150 (74%) patients had MOG-IgG that recognised the immunodominant proline42 (P42) epitope and 115 (57%) recognised histidine103/serine104 (H103/S104). Fifty-two (26%) patients had non-P42 MOG-IgG and showed an increased risk of a relapsing course (HR 1.7; 95% CI 1.15 to 2.60, p=0.009). Relapse-freedom was shorter in patients with non-P42 MOG-IgG (p=0.0079). Non-P42 MOG-IgG epitope status remained unchanged from onset throughout the disease course and was a strong predictor of a relapsing course in patients with unilateral optic neuritis (HR 2.7, 95% CI 1.06 to 6.98, p=0.038), with high specificity (95%, 95% CI 77% to 100%) and positive predictive value (85%, 95% CI 45% to 98%). CONCLUSIONS: Non-P42 MOG-IgG predicts a relapsing course in a significant subgroup of MOGAD patients. Patients with unilateral optic neuritis, the most frequent MOGAD phenotype, can reliably be tested at onset, regardless of age and sex. Early detection and specialised management in these patients could minimise disability and improve long-term outcomes.


Asunto(s)
Autoanticuerpos , Inmunoglobulina G , Glicoproteína Mielina-Oligodendrócito , Recurrencia , Humanos , Glicoproteína Mielina-Oligodendrócito/inmunología , Masculino , Femenino , Adulto , Persona de Mediana Edad , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Epítopos/inmunología , Biomarcadores/sangre , Neuritis Óptica/inmunología , Neuritis Óptica/sangre
4.
In. U.S. Central United States Earthquake Consortium (CUSEC). Mitigation and damage to the built environment. Memphis, Tennessee, U.S. Central United States Earthquake Consortium (CUSEC), 1993. p.275-84, ilus.
Monografía en En | Desastres | ID: des-6676

RESUMEN

Multistory reinforced concrete factory/warehouses were built throughout the United States from the late 1800's to the 1939's. Thesebuilding the typically three to eight stories tall and have flat slabs, drop panels, large column capitals, approximately square bays, and reinforced concrete frames at the perimeter of the building. The perimeter frames are generally infilled with unreinforced masonry and large windows, The buildings were designed to carry very heavy vertical loads (AU)


Asunto(s)
Terremotos , Industria de la Construcción , Materiales de Construcción , Medición de Riesgo , Ingeniería
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA